CLBS - CLBS STOCK NEWS

Caladrius Biosciences (Nasdaq: CLBS) announced participation in Landmark’s 10th Annual Investing for Cures Virtual Forum on September 16-17, 2020. The event, aimed at fostering dialogue between investors and healthcare innovators, will feature a presentation by David J. Mazzo, Ph.D., CEO, on September 16 at 2:10 p.m. EDT. Caladrius focuses on developing cellular therapies to reverse diseases, with candidates including CLBS119 for severe COVID-19 lung damage and HONEDRA® for critical limb ischemia, among others.

Caladrius Biosciences (Nasdaq: CLBS) announced the trademark registration of HONEDRA® in Japan for its product candidate CLBS12, aimed at treating Critical Limb Ischemia and Buerger's Disease. This approval, granted by the Japan Patent Office, marks a significant step towards commercialization, expected by mid-2022. Additionally, Caladrius received a new patent for its CD34+ cell therapy technology, enhancing its intellectual property portfolio. The company's focus remains on advancing cellular therapies that aim to reverse rather than manage disease.

Caladrius Biosciences (Nasdaq: CLBS) announced its participation in the H.C. Wainwright 22nd Annual Global Investment Conference, set for September 14-16, 2020. David J. Mazzo, Ph.D., President and CEO, will present on September 15 at 1:00 p.m. EDT. The company focuses on cellular therapies aimed at reversing diseases, with product candidates including CLBS119 for severe COVID-19 lung damage and several therapies for ischemic diseases. Their lead product, HONEDRA®, is under potential conditional approval in Japan for critical limb ischemia.

Caladrius Biosciences (NASDAQ:CLBS) announced its participation in the LD 500 virtual investor conference from September 1-4, 2020. CEO David J. Mazzo will present on September 1 at 11:40 a.m. ET, followed by virtual one-on-one meetings with analysts and investors. The presentation will be available for live streaming and replay on the company’s website. Caladrius is focused on cellular therapies aimed at reversing diseases, with key products including CLBS119 for severe COVID-19 lung damage and treatments for ischemic diseases. For more details, visit caladrius.com.

Caladrius Biosciences (Nasdaq: CLBS) announces advancements in clinical programs and a strong cash position. The Company plans to initiate the CLBS119 trial in 3Q 2020 to address COVID-19 induced lung damage, utilizing CD34+ cell technology. The CLBS12 study in Japan shows promising outcomes for critical limb ischemia, while the Phase 2b trial for CLBS16 targeting coronary microvascular dysfunction is slated to begin by late 2020. Caladrius raised nearly $30 million in new capital, extending its cash runway through 2021. The Company reported a net income of $6.6 million for Q2 2020, driven by a tax benefit from net operating losses.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) announced it will report its financial results for the second quarter of 2020 on August 13, 2020. The conference call for investors is scheduled for 4:30 p.m. ET on the same day to discuss results and provide business updates. Caladrius is focused on cellular therapies aimed at reversing diseases, with ongoing projects including CLBS119 for severe COVID-19 lung damage and CLBS12, CLBS16, and CLBS14 for ischemic diseases. These candidates are at various stages, with promising clinical trials underway.

Caladrius Biosciences (Nasdaq: CLBS) announced the appointment of Dr. Michael H. Davidson to its Board of Directors. Dr. Davidson, a prominent figure in preventative cardiology, brings extensive experience, having co-founded Corvidia Therapeutics, sold recently for $2.1 billion. His background includes leadership roles in clinical research, regulatory approval, and lipidology. This appointment is expected to assist Caladrius in advancing its clinical programs and product pipeline, including its innovative CD34+ cell therapies targeting severe COVID-19 lung damage and ischemic diseases.

Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage biopharmaceutical firm, will present its CD34+ cell therapy candidate, CLBS119, at the BioNJ COVID-19 Rapid Fire Research Showcase on June 5, 2020. This innovative therapy aims to repair lung damage caused by severe COVID-19 infections. The company is also advancing other cell therapy products, including CLBS12 for critical limb ischemia and CLBS16 for coronary microvascular dysfunction, with various stages of clinical trials underway. Further details about these developments are available on their website.

Caladrius Biosciences (Nasdaq: CLBS) has completed a registered direct offering, selling 2,084,850 shares at $2.0625 per share, raising approximately $4.3 million. The offering included unregistered warrants for an additional 1,042,425 shares, exercisable at the same price and expiring in five and a half years. Proceeds will be used for working capital and advancing its CD34+ technology-based clinical programs. H.C. Wainwright & Co. led the placement, with Brookline Capital Markets as co-agent.